New antibody AHA-1031 shows potential in treating non small cell lung cancer resistant to immunotherapy, offering new hope.

The development of bacterial vaccines has played a critical role in combating infectious diseases, significantly reducing mortality and morbidity worldwide.

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

Antibody drugs have reshaped how we treat diseases. By harnessing the immune system to destroy tumours or temper excessive inflammation in autoimmune disorders, these therapeutics have become ...

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their ...

Introduction Therapeutic antibodies are laboratory-engineered proteins designed to replicate the immune system's natural ability to combat dise ...

Influenza A virus particles strategically adapt their shape -- to become either spheres or larger filaments -- to favor their ability to infect cells depending on environmental conditions, according ...

Korean researchers develop Trojan horse method to produce antibodies in tumors Innovative nanoparticle platform creates tumor ...

HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...

IgGenix, Inc., a clinical-stage biotechnology company pioneering innovative treatments for immune-mediated diseases, today ...